Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.

Meng XW, Heldebrant MP, Flatten KS, Loegering DA, Dai H, Schneider PA, Gomez TS, Peterson KL, Trushin SA, Hess AD, Smith BD, Karp JE, Billadeau DD, Kaufmann SH.

J Biol Chem. 2010 Jan 8;285(2):888-902. doi: 10.1074/jbc.M109.057638. Epub 2009 Nov 3.

2.

Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.

Mesa RA, Loegering D, Powell HL, Flatten K, Arlander SJ, Dai NT, Heldebrant MP, Vroman BT, Smith BD, Karp JE, Eyck CJ, Erlichman C, Kaufmann SH, Karnitz LM.

Blood. 2005 Jul 1;106(1):318-27. Epub 2005 Mar 22.

3.

Dynamin 2 regulates T cell activation by controlling actin polymerization at the immunological synapse.

Gomez TS, Hamann MJ, McCarney S, Savoy DN, Lubking CM, Heldebrant MP, Labno CM, McKean DJ, McNiven MA, Burkhardt JK, Billadeau DD.

Nat Immunol. 2005 Mar;6(3):261-70. Epub 2005 Feb 6.

PMID:
15696170
4.

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM.

J Clin Oncol. 2004 May 15;22(10):1797-806. Epub 2004 Apr 5.

PMID:
15067028
5.

Heterogeneous role of caspase-8 in fenretinide-induced apoptosis in epithelial ovarian carcinoma cell lines.

Kalli KR, Devine KE, Cabot MC, Arnt CR, Heldebrant MP, Svingen PA, Erlichman C, Hartmann LC, Conover CA, Kaufmann SH.

Mol Pharmacol. 2003 Dec;64(6):1434-43.

PMID:
14645674
6.

Microtubule destabilization and nuclear entry are sequential steps leading to toxicity in Huntington's disease.

Trushina E, Heldebrant MP, Perez-Terzic CM, Bortolon R, Kovtun IV, Badger JD 2nd, Terzic A, Estévez A, Windebank AJ, Dyer RB, Yao J, McMurray CT.

Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12171-6. Epub 2003 Oct 3.

7.

Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas.

Thomé SD, Loprinzi CL, Heldebrant MP.

Mayo Clin Proc. 2002 Sep;77(9):913-7.

PMID:
12233924
8.

Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ.

Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ, Kaufmann SH.

J Biol Chem. 2002 Nov 15;277(46):44236-43. Epub 2002 Sep 5.

9.

Supplemental Content

Loading ...
Support Center